Relationship between lipoprotein-associated phospholipase A2 and ambulatory arterial stiffness index in patients with essential hypertension

doi:10.3877/cma.j.issn.1674-0785.2020.09.003

Abstract

Abstract:

Objective

To investigate the relationship between lipoprotein-associated phospholipase A2 (Lp-PLA2) and ambulatory arterial stiffness index (AASI) in patients with essential hypertension.

Methods

A total of 178 patients with essential hypertension hospitalized at Xuzhou Central Hospital from October 2018 to October 2019 were enrolled. AASI was calculated through 24-hour ambulatory blood pressure monitoring. According to the median value of AASI, the patients were divided to either a low AASI group (less than the AASI median; n=89) or a high AASI group (equal to or above the AASI median; n=89). Differences of age, gender, body mass index, smoking history, diabetes history, systolic blood pressure, diastolic blood pressure, fasting blood glucose, triglyceride (TG), total cholesterol (TC), low density lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol (HDL-C), estimated glomerular filtration rate (eGFR), uric acid, and Lp-PLA2 levels between the two groups were evaluated. The correlation between Lp-PLA2 and AASI was assessed. Multivariate linear regression analysis was performed to analyze the association of Lp-PLA2 and clinical data with AASI.

Results

Compared with the low AASI group, age [(67.87±14.23) years vs (55.65±14.59) years], systolic blood pressure [(136.96±16.23) mmHg vs (128.35±14.23) mmHg], fasting blood glucose [(5.95±2.26) mmol/L vs (5.36±0.82) mmol/L], and Lp-PLA2 [127 (100, 169) ng/ml vs 103 (86, 150) ng/ml] were significantly higher, and diastolic blood pressure [(72.26±12.87) mmHg vs (77.30±10.49) mmHg] and eGFR [(92.49±18.66) ml/(min?1.73 m²) vs (106.90±15.83) ml/(min?1.73 m²)] were significantly lower in the high AASI group (t=-5.654, P<0.001; t=-3.762, P<0.001; t=-2.296, P=0.024; Z=-2.470, P=0.014; t=2.867, P=0.005; t=5.553, P<0.001). Spearman correlation analysis showed a positive correlation between Lp-PLA2 and AASI (r=0.237, P<0.001). Multivariate linear regression analysis showed that systolic blood pressure (β=0.431, P<0.001), diastolic blood pressure (β=-0.371, P<0.001), fasting blood glucose (β=0.160, P=0.013), and Lp-PLA2 (β=0.152, P=0.022) were independent risk factors for AASI.

Conclusion

There is a positive correlation between Lp-PLA2 and AASI in patients with essential hypertension.

Key words: Essential hypertension, Lipoprotein-associated phospholipase A2, Ambulatory arterial stiffness index

Bin Zong, Bing Han, Xuefeng Zong. Relationship between lipoprotein-associated phospholipase A2 and ambulatory arterial stiffness index in patients with essential hypertension[J]. Chinese Journal of Clinicians(Electronic Edition), 2020, 14(09): 680-684.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcyszz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0785.2020.09.003

https://zhlcyszz.cma-cmc.com.cn/EN/Y2020/V14/I09/680

Figures/Tables 2

References 18

1	DeLoach SS, Townsend RR. Vascular stiffness: its measurement and significance for epidemiologic and outcome studies [J]. Clin J Am Soc Nephrol, 2008, 3(1): 184-192.
2	林铮，王振华，吴玉塘. 臂踝脉搏波传导速度及踝臂指数对高血压患者早期动脉硬化的诊断价值 [J]. 中国动脉硬化杂志, 2015, 23(11): 1149-1152.
3	Li Y, Wang JG, Eamon D, et al. Ambulatory arterial stiffness index derived from 24-hour ambulatory blood pressure monitoring [J]. Hypertension, 2006, 47(3): 359-364.
4	Li JJ, Fang CH, Jiang H, et al. Activation of nuclear factor-kappaB and correlation with elevated plasma C-reactive protein in patients with unstable angina [J]. Heart Lung Cric, 2004, 13(2): 173-178.
5	Wang J, Tan GJ, Han LN, et al. Novel biomarkers for cardiovascular risk prediction [J]. J Geriatr Caidiol, 2017, 14(2): 135-150.
6	中国高血压防治指南修订委员会. 中国高血压防治指南2010 [J]. 中华心血管病杂志, 2011, 39(7): 579-615.
7	全国eGFR课题协作组. MDRD方程在我国慢性肾脏病患者中的改良和评估 [J]. 中华肾脏病杂志, 2006, 10(22): 589-595.
8	邓敏，欧阳辉，刘涛. 动态动脉硬化指数在高血压患者临床应用中的研究进展 [J]. 中国动脉硬化杂志, 2017, 25(12): 1271-1296.
9	Dolan E, Thijs L, Li Y, et al. Ambulatory arterial stiffness index as a predictor of cardiovascular mortality in the Dublin Outcome Study [J]. Hypertension, 2006, 47(3): 365-370.
10	Bastos, Filipa S, Joana S, et al. The prognostic value of ambulatory arterial stiffness index as a predictor of cardiovascular events in resistant hypertensive patients [J]. J Hypertens, 2015, 33(Suppl 1): e74.
11	Eriksen BO, Stefansson VT, Jenssen TG, et al. High ambulatory arterial stiffness index is an independent risk factor for rapid age-related glomemlar filtrationrate decline in the general middle-aged population [J]. Hypertension, 2017, 69(4): 651-659.
12	Delgado P, Chacón P, Penalba A, et al. Temporal profile and prognostic value of Lp-PLA2 mass and activity in the acute stroke setting [J]. Atherosclerosis, 2012, 220(2): 532-536. URL
13	Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease [J]. Atherosclerosis, 2000, 150(2): 413-419.
14	Cao Y, Stafforini DM, Zimmerman GA, et al. Expression of plasma platelet-activating factor acetylhydrolase in transcriptionally regulated by mediators of inflammation [J]. J Biol Chem, 1998, 272(7): 4012-4020.
15	Macphee CH, Nelson J, Zalewski A. Lipoprotein-associated phospholipase A2 as a target of therapy [J]. Curr Opin Lipidol, 2005, 16(4): 442-446.
16	Packard CJ, O′Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group [J]. N Engl J Med, 2000, 343(16): 1148-1155.
17	Yang L, Liu Y, Wang S, et al. Association between Lp-PLA2 and coronary heart disease in Chinese patients [J]. J Intern Med Res, 2017, 45(1): 159-169.
18	Li Z, Liu J, Shen Y, et al. Increased lipoprotein-associated phospholipase A2 activity portends an increased risk of resistant hypertension [J]. Lipids Health Dis, 2016, 15(1): 15-20.

临床资料	低AASI组（89例）	高AASI组（89例）	统计值	P值
年龄（岁，±s）	55.65±14.59	67.87±14.23	t=-5.654	<0.001
男性[例（%）]	54（60.7）	51（57.3）	χ²=0.209	0.648
体质量指数（kg/m²，±s）	26.05±3.53	25.60±3.41	t=0.869	0.386
吸烟史[例（%）]	13（14.6）	10（11.2）	χ²=0.449	0.503
糖尿病病史[例（%）]	8（9.0）	15（16.9）	χ²=2.447	0.118
收缩压（mmHg，±s）	128.35±14.23	136.96±16.23	t=-3.762	<0.001
舒张压（mmHg，±s）	77.30±10.49	72.26±12.87	t=2.867	0.005
空腹血糖（mmol/L，±s）	5.36±0.82	5.95±2.26	t=-2.296	0.024
TC（mmol/L，±s）	4.63±1.12	4.33±1.08	t=1.837	0.068
TG（mmol/L，±s）	1.88±1.32	1.94±1.50	t=-0.287	0.774
HDL-C（mmol/L，±s）	1.25±0.25	1.21±0.30	t=0.849	0.397
LDL-C（mmol/L，±s）	2.80±0.89	2.59±0.88	t=1.551	0.123
eGFR[ml/（min•1.73 m²），±s]	106.90±15.83	92.49±18.66	t=5.553	<0.001
尿酸（μmol/L，±s）	334.12±94.40	334.77±95.68	t=-0.045	0.964
Lp-PLA2[ng/ml，M（Q_R）]	103（86~150）	127（100~169）	Z=-2.470	0.014
AASI（±s）	0.34±0.09	0.58±0.10	t=-17.247	<0.001

临床资料	低AASI组（89例）	高AASI组（89例）	统计值	P值
年龄（岁，±s）	55.65±14.59	67.87±14.23	t=-5.654	<0.001
男性[例（%）]	54（60.7）	51（57.3）	χ²=0.209	0.648
体质量指数（kg/m²，±s）	26.05±3.53	25.60±3.41	t=0.869	0.386
吸烟史[例（%）]	13（14.6）	10（11.2）	χ²=0.449	0.503
糖尿病病史[例（%）]	8（9.0）	15（16.9）	χ²=2.447	0.118
收缩压（mmHg，±s）	128.35±14.23	136.96±16.23	t=-3.762	<0.001
舒张压（mmHg，±s）	77.30±10.49	72.26±12.87	t=2.867	0.005
空腹血糖（mmol/L，±s）	5.36±0.82	5.95±2.26	t=-2.296	0.024
TC（mmol/L，±s）	4.63±1.12	4.33±1.08	t=1.837	0.068
TG（mmol/L，±s）	1.88±1.32	1.94±1.50	t=-0.287	0.774
HDL-C（mmol/L，±s）	1.25±0.25	1.21±0.30	t=0.849	0.397
LDL-C（mmol/L，±s）	2.80±0.89	2.59±0.88	t=1.551	0.123
eGFR[ml/（min•1.73 m²），±s]	106.90±15.83	92.49±18.66	t=5.553	<0.001
尿酸（μmol/L，±s）	334.12±94.40	334.77±95.68	t=-0.045	0.964
Lp-PLA2[ng/ml，M（Q_R）]	103（86~150）	127（100~169）	Z=-2.470	0.014
AASI（±s）	0.34±0.09	0.58±0.10	t=-17.247	<0.001

自变量	B值	标准误	β值	t值	P值
常数	0.187	0.155		1.207	0.229
年龄	0.00075	0.00095	0.077	0.787	0.432
收缩压	0.00412	0.00082	0.431	5.034	<0.001
舒张压	-0.00468	0.00124	-0.371	-3.787	<0.001
空腹血糖	0.01402	0.00561	0.160	2.499	0.013
eGFR	0.00079	0.00072	-0.097	-1.096	0.275
Lp-PLA2	0.00022	0.00010	0.152	2.307	0.022

自变量	B值	标准误	β值	t值	P值
常数	0.187	0.155		1.207	0.229
年龄	0.00075	0.00095	0.077	0.787	0.432
收缩压	0.00412	0.00082	0.431	5.034	<0.001
舒张压	-0.00468	0.00124	-0.371	-3.787	<0.001
空腹血糖	0.01402	0.00561	0.160	2.499	0.013
eGFR	0.00079	0.00072	-0.097	-1.096	0.275
Lp-PLA2	0.00022	0.00010	0.152	2.307	0.022

[1]	Shuyi Zeng, Xiangwen Liang, Zhihai Lin, Yiyi Li, Zheng Ling, Zhengdong Wang. Relationship of 24-hour urinary protein and blood pressure variability with sleep disorders in patients with essential hypertension [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(01): 48-53.
[2]	Xiaoguang Yao, Jing Hong, Mei Li, Xiufang Li, Junli Hu, Delian Zhang, Guijuan Chang, Keming Zhou, Nanfang Li. Correlation between plasma aldosterone concentration and pulse pressure in patients with essential hypertension in different positions [J]. Chinese Journal of Clinicians(Electronic Edition), 2017, 11(13): 1965-1969.
[3]	Zhengding Zhang, Yanjie Tong, Xiaonong Fan. A preliminary exploration on the relationship of Shi Xuemin′s of " Qihai theory" and the phlegm-dampness constitution of hypertension [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2018, 07(03): 89-92.
[4]	Jianrong Wu, Yijing Ma, Chunmei Ma. Preliminary analysis of myeloperoxidase, oxidized low density lipoprotein and lipoprotein-associated phospholipase A2 in the plasma of healthy adults [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2016, 04(02): 116-121.
[5]	Lanping Gu, Xinjuan Xu, Rongxiu Zhang. Relationship between angiotensin-converting enzyme gene I/D polymorphism and antihypertensive efficacy of ACE inhibitors in hypertensive patients of Uyghur and Kazak in Xinjiang [J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(04): 225-229.

Please choose a citation manager

Content to export